For: | Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes 2021; 12(7): 932-938 [PMID: 34326946 DOI: 10.4239/wjd.v12.i7.932] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v12/i7/932.htm |
Number | Citing Articles |
1 |
Jiaqi Zhang, Chuan Xing, Bing He. Sodium-glucose cotransporter-2 inhibitors for improving endocrine and metabolic profiles in overweight and obese individuals with polycystic ovary syndrome: a meta-analysis protocol. BMJ Open 2022; 12(4): e058260 doi: 10.1136/bmjopen-2021-058260
|
2 |
Lanlan Zhang, Zun Wang, Lingnan Kong, Huan Liu, Ziyang Ma, Miaomiao Xu, Suliya Yushanjiang, Dongzhi Yuan, Linlin Yu. Effect of SGLT2 Inhibitors on Improving Glucolipid Metabolism and Reproductive Hormone Status in Overweight/Obese Women with PCOS: A Systematic Review and Meta-Analysis. Reproductive Sciences 2024; 31(5): 1190 doi: 10.1007/s43032-023-01415-5
|
3 |
Amin Liaghatdar, Sadegh Mazaheri-Tehrani, Mohammad Fakhrolmobasheri. Management of Hypertension in Patients With Polycystic Ovarian Syndrome: A Mini-Review. Cardiology in Review 2024; doi: 10.1097/CRD.0000000000000635
|
4 |
Mali Wu, Jie Zhang, Ran Gu, Fangfang Dai, Dongyong Yang, Yajing Zheng, Wei Tan, Yifan Jia, Bingshu Li, Yanxiang Cheng. The role of Sirtuin 1 in the pathophysiology of polycystic ovary syndrome. European Journal of Medical Research 2022; 27(1) doi: 10.1186/s40001-022-00746-4
|
5 |
Jiaqi Zhang, Chuan Xing, Xiangyi Cheng, Bing He. Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1003238
|
6 |
Hosna Mohammad Sadeghi, Ida Adeli, Daniela Calina, Anca Oana Docea, Taraneh Mousavi, Marzieh Daniali, Shekoufeh Nikfar, Aristidis Tsatsakis, Mohammad Abdollahi. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. International Journal of Molecular Sciences 2022; 23(2): 583 doi: 10.3390/ijms23020583
|
7 |
Han Zhao, Jiaqi Zhang, Xiangyi Cheng, Xiaozhao Nie, Bing He. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research 2023; 16(1) doi: 10.1186/s13048-022-01091-0
|
8 |
Amanda Vitória Ribeiro de Lima, Giovanna Freire Guimarães Amantéa, Jamille Mirelle de Oliveira Cardoso, Larissa Mirelle de Oliveira Pereira, Douglas Roberto Guimarães Silva. ABORDAGENS TERAPÊUTICAS PARA A SÍNDROME DO OVÁRIO POLICÍSTICO (SOP) COM ÊNFASE NA RESISTÊNCIA À INSULINA. Revista Contemporânea 2024; 4(6): e4169 doi: 10.56083/RCV4N6-107
|
9 |
Tamara Coffin, Jadzia Wray, Ramsagar Sah, Mary Maj, Reetuparna Nath, Shreya Nauhria, Sabyasachi Maity, Samal Nauhria. A Review and Meta-Analysis of the Prevalence and Health Impact of Polycystic Ovary Syndrome Among Medical and Dental Students. Cureus 2023; doi: 10.7759/cureus.40141
|
10 |
Decio Armanini, Marco Boscaro, Luciana Bordin, Chiara Sabbadin. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. International Journal of Molecular Sciences 2022; 23(8): 4110 doi: 10.3390/ijms23084110
|
11 |
Dejana Rakic, Vladimir Jakovljevic, Nikola Jovic, Marija Bicanin Ilic, Aleksandra Dimitrijevic, Tatjana Vulovic, Petar Arsenijevic, Jasmina Sretenovic, Maja Nikolic, Vladimir Petrovich Fisenko, Stefani Bolevich, Gala Zarkovic, Jovana Joksimovic Jovic. The Potential of SGLT-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: The Current Status and Future Perspectives. Biomedicines 2023; 11(4): 998 doi: 10.3390/biomedicines11040998
|
12 |
Mojtaba Sarvestani, Alireza Rajabzadeh, Tahereh Mazoochi, Mansooreh Samimi, Mohsen Navari, Faezeh Moradi. Use of placental-derived mesenchymal stem cells to restore ovarian function and metabolic profile in a rat model of the polycystic ovarian syndrome. BMC Endocrine Disorders 2024; 24(1) doi: 10.1186/s12902-024-01688-0
|